Colon polyps medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Removing from Primary care |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The mainstay of treatment for colon polyps is surgery. Aspirin is recommended to prevent recurrent polyps or conversion of colon polyps to colorectal cancer. | The mainstay of treatment for colon polyps is [[surgery]]. [[Aspirin]] is recommended to prevent recurrent [[Polyp|polyps]] or conversion of colon polyps to [[colorectal cancer]]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
*The mainstay of treatment for colon polyps is surgery. | *The mainstay of treatment for colon polyps is [[surgery]]. | ||
*Aspirin is recommended to prevent recurrent polyps. | *[[Aspirin]] is recommended to prevent recurrent [[Polyp|polyps]]. | ||
*The United States Preventive Services Task Force recommend low-dose Aspirin for adults aged 50 to 59 years for at least 10 years, to prevent the conversion of colon polyps to colorectal cancer.<ref>Whitlock EP, Williams SB, Burda BU, et al. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 132.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321643/</ref><ref name="pmid27064261"><ref>{{cite journal |vauthors=Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV |title=Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force |journal=Ann. Intern. Med. |volume=164 |issue=12 |pages=826–35 |year=2016 |pmid=27064261 |doi=10.7326/M15-2112 |url=}}</ref><ref>Chubak J, Kamineni A, Buist DSM, et al. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 133.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321661/</ref><ref name="pmid27064573">{{cite journal |vauthors=Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP |title=Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force |journal=Ann. Intern. Med. |volume=164 |issue=12 |pages=777–86 |year=2016 |pmid=27064573 |doi=10.7326/M15-2129 |url=}}</ref> | *The [[United states preventive services task force recommendations scheme|United States Preventive Services Task Force]] recommend low-dose [[Aspirin]] for adults aged 50 to 59 years for at least 10 years, to prevent the conversion of colon polyps to [[colorectal cancer]].<ref>Whitlock EP, Williams SB, Burda BU, et al. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 132.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321643/</ref><ref name="pmid27064261"><nowiki><ref></nowiki>{{cite journal |vauthors=Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV |title=Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force |journal=Ann. Intern. Med. |volume=164 |issue=12 |pages=826–35 |year=2016 |pmid=27064261 |doi=10.7326/M15-2112 |url=}}</ref><ref>Chubak J, Kamineni A, Buist DSM, et al. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 133.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321661/</ref><ref name="pmid27064573">{{cite journal |vauthors=Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP |title=Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force |journal=Ann. Intern. Med. |volume=164 |issue=12 |pages=777–86 |year=2016 |pmid=27064573 |doi=10.7326/M15-2129 |url=}}</ref> | ||
** Preferred regimen (1): Aspirin ≥75 mg PO qd | ** Preferred regimen (1): [[Aspirin]] ≥75 mg PO qd | ||
** Preferred regimen (2): Aspirin 325 mg PO every other day | ** Preferred regimen (2): [[Aspirin]] 325 mg PO every other day | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 21:01, 29 July 2020
|
Colon polyps Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Colon polyps medical therapy On the Web |
|
American Roentgen Ray Society Images of Colon polyps medical therapy |
|
Risk calculators and risk factors for Colon polyps medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
The mainstay of treatment for colon polyps is surgery. Aspirin is recommended to prevent recurrent polyps or conversion of colon polyps to colorectal cancer.
Medical Therapy
- The mainstay of treatment for colon polyps is surgery.
- Aspirin is recommended to prevent recurrent polyps.
- The United States Preventive Services Task Force recommend low-dose Aspirin for adults aged 50 to 59 years for at least 10 years, to prevent the conversion of colon polyps to colorectal cancer.[1][2][3][4]
References
- ↑ Whitlock EP, Williams SB, Burda BU, et al. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 132.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321643/
- ↑ <ref>Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV (2016). "Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force". Ann. Intern. Med. 164 (12): 826–35. doi:10.7326/M15-2112. PMID 27064261.
- ↑ Chubak J, Kamineni A, Buist DSM, et al. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 133.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321661/
- ↑ Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP (2016). "Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force". Ann. Intern. Med. 164 (12): 777–86. doi:10.7326/M15-2129. PMID 27064573.